Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01221441 · ClinicalTrials.gov registry record · Phase 2
Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
A Phase 2 study, sponsored by Kolon TissueGene.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT01221441 is a Phase 2 study that has completed, run by Kolon TissueGene. The registered enrollment target is 102 participants.
The verdict
NCT01221441, a Phase 2 study, has completed, sponsored by Kolon TissueGene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this study is to see if we can safely regenerate cartilage without invasive surgery using a biologic product called TissueGene-C.
Interventions
- DRUG Normal Saline
- BIOLOGICAL TissueGene-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2011-05 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01221441
The ClinicalTrials.gov registry entry for NCT01221441 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kolon TissueGene, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT01221441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01221441 about?
NCT01221441 is a clinical study titled "Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee". The purpose of this study is to see if we can safely regenerate cartilage without invasive surgery using a biologic product called TissueGene-C.
What is the current status of trial NCT01221441?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2011-05. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01221441?
The interventions under investigation include: Normal Saline (DRUG), TissueGene-C (BIOLOGICAL).
Who is sponsoring clinical trial NCT01221441?
This trial is sponsored by Kolon TissueGene, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.